High incidence of the cardiac variant of fabry disease revealed by newborn screening in the Taiwan Chinese population

Circulation: Cardiovascular Genetics

Volumn 2, Issue 5, 2009, Pages 450-456

  Lin, Hsiang Yu ^a,b   Chong, Kah Wai ^a   Hsu, Ju Hui ^c   Yu, Hsiao Chi ^c   Shih, Chun Che ^a,c   Huang, Cheng Hung ^c   Lin, Shing Jong ^a,c   Chen, Chen Huan ^a,c   Chiang, Chuan Chi ^d   Ho, Huey Jane ^e   Lee, Pi Chang ^c   Kao, Chuan Hong ^c   Cheng, Kang Hsiang ^c   Hsueh, Chuen ^f   Niu, Dau Ming ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d Chinese Foundation of Health   (Taiwan)

^e Taipei Institute of Pathology   (Taiwan)

^f CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Fabry disease; Hypertrophic cardiomyopathy; Hypertrophy; Newborn screening; Taiwan Chinese population

Indexed keywords

ADENINE; ALANINE; ALPHA GALACTOSIDASE; ARGININE; CYSTEINE; GLYCINE; GUANINE; HISTIDINE; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; SERINE; THREONINE; TRYPTOPHAN; VALINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CHINESE; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME ASSAY; FABRY DISEASE; FEMALE; HEART DISEASE; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; INCIDENCE; INTRON; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN SCREENING; PREVALENCE; PRIORITY JOURNAL; TAIWAN; ADOLESCENT; ASIAN; BLOOD; ENZYMOLOGY; GENETICS; MIDDLE AGED; MUTATION; PEDIGREE;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOMYOPATHY, HYPERTROPHIC; FABRY DISEASE; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; MIDDLE AGED; MUTATION; NEONATAL SCREENING; PEDIGREE; TAIWAN; YOUNG ADULT;

EID: 77949893047     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.862920     Document Type: Article

References (35)

1. Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:3733-3774.
2. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249-254.
3. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991;324:395-399.
4. Chimenti C, Ricci R, Pieroni M, Natale L, Russo MA, Frustaci A. Cardiac variant of Fabry's disease mimicking hypertrophic cardiomyopathy. Cardiologia. 1999;44:469-473.
5. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart. 2003;89:929-930.
6. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-293.
7. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002;105: 1407-1411.
8. Monserrat L, Gimeno-Blanes JR, Marín F, Hermida-Prieto M, García-Honrubia A, Pérez I, Fernández X, de Nicolas R, de la Morena G, Payá E, Yagüe J, Egido J. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007; 50:2399-2403.
9. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez ALD, Eng CE, Tanaka H, Tei C, Desnick RJ. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003;64:801-807.
10. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004;15:1323-1329. (Pubitemid 38526014)
11. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18:1547-1557.
12. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524-529.
13. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21: 345-354.
14. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146:77-86.
15. Pierre-Louis B, Kumar A, Frishman WH. Fabry disease: cardiac manifestations and therapeutic options. Cardiol Rev. 2009;17:31-35.
16. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308: 195-196. (Pubitemid 32537628)
17. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004;114:909-916.
18. Li Y, Scott CR, Chamoles NA, Ghavami A, Pinto BM, Turecek F, Gelb MH. Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. Clin Chem. 2004;50:1785-1796.
19. Pagliardini S, Spada M. A simple and rapid approach for screening lysosomal storage disorders. J Inherit Metab Dis. 2003;26:S1.
20. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79: 31-40.
21. Sheu SS, Chan LP, Liao SC, Hsiao KJ, Shu KH, Lu YS, Cheng CH, Lian JD. Fabry's disease: clinical, pathologic and biochemical manifestations in two Chinese males. Zhonghua Yi Xue Za Zhi. 1994;54: 368-372.
22. Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973;81:157-171.
23. Chen CH, Shyu PW, Wu SJ, Sheu SS, Desnick RJ, Hsiao KJ. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no 169. Hum Mutat. 1998;11:328-330.
24. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC, Fan JQ. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J. 2007;406:285-295.
25. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene. Hum Mol Genet. 1994;3: 1795-1799.
26. Spada M, Marongiu A, Voglino G, Merlino S, Alluto A, La Dolcetta M, Pagliardini S. Molecular study in 20 unrelated male patients with Fabry disease: the A143T genotype correlates with the late-onset end-stage nephropathy. J Inherit Metab Dis. 2003;26:171.
27. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med. 1997; 3:174-182.
28. Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, Desnick RJ. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83: 1390-1399.
29. Ishii S, Nakao S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet. 2002;70:994-1002.
30. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt- Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112-128.
31. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007;9:34-45.
32. Chimenti C, Pieroni M, Morgante E, Antuzzi D, Russo A, Russo MA, Maseri A, Frustaci A. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004;110: 1047-1053.
33. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol. 2002;40:1668-1674.
34. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24:2102-2111 [Epub ahead of print].
35. Linthorst GE, Vedder AC, Aerts JM, Hollak CE. Screening for Fabry disease using whole blood spots fails to identify one-third of female carriers. Clin Chim Acta. 2005;353:201-203.